Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genus Oncology has got Orphan Drug status from the US Food and Drug Administration's (FDA) Office of Orphan Products Development for Mucin 1 (MUC1) targeting peptide, GO-203-2c, for the treatment of pancreatic cancer.
Subscribe to our email newsletter
The company’s lead drug candidate, GO-203-2c is currently being studied in a Phase I trial which aims to determine the safety and tolerability, and potential anti-tumor activity of the drug.
Genus Oncology president and CEO Stephen Thompson said based on their results of treating pancreatic cancer in preclinical models, they believe MUC1 targeting technologies have the potential to significantly impact the treatment and outcomes of this difficult to treat disease.